Background
Berlimatoxumab (ASN-2) is an antibody. Berlimatoxumab can be used for experiment research.• Separately or combined, LukG/LukH is functionally unique compared to other staphylococcal bicomponent leukotoxins., PMID:24586678• Molecular mechanism of leukocidin GH-integrin CD11b/CD18 recognition and species specificity., PMID:31852826• Context matters: The importance of dimerization-induced conformation of the LukGH leukocidin of Staphylococcus aureus for the generation of neutralizing antibodies., PMID:27467113• Structure-function analysis of heterodimer formation, oligomerization, and receptor binding of the Staphylococcus aureus bi-component toxin LukGH., PMID:25371205• Adaptive laboratory evolution and independent component analysis disentangle complex vancomycin adaptation trajectories., PMID:35858453• Human antibody responses against non-covalently cell wall-bound Staphylococcus aureus proteins., PMID:29459694• Identification of a novel Staphylococcus aureus two-component leukotoxin using cell surface proteomics., PMID:20661294• Serum neutralizing antibody after rabies postexposure prophylaxis., PMID:945973• Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening., PMID:29176494• Vitamin E regulates mitochondrial hydrogen peroxide generation., PMID:10490278